Jimmy is joined by Dr. Robert Malone to discuss the Trump administration plan to separate the measles, mumps, and rubella vaccination, with Malone arguing that the move could create a regulatory pathway for expanded use of mRNA vaccine technology. He explains his interpretation of FDA “platform technology” rules, claiming that once an mRNA platform is established through multiple licensed products, companies such as Pfizer/BioNTech and Moderna could potentially adapt the platform to new vaccine targets without repeating the full development process, while he characterizes the market as an oligopoly. The two then focus on the possibility of developing mRNA versions of measles, mumps, and rubella vaccines, which Malone presents as a hypothesis for why separating the traditional MMR vaccines could be significant and expressing concerns about the safety, regulatory, and competitive implications. The segment concludes with Malone criticizing aspects of the Trump administration and HHS, saying he supported Trump but has become uncomfortable with some administration policies and business relationships, while distinguishing those concerns from actions he considers positive. Robert Malone on Twitter: https://twitter.com/RWMaloneMD Robert Malone’s Substack: https://www.malone.news/ Become a Premium Member: https://www.jimmydore.com/premium-membership Go to a Live Show: https://www.jimmydore.com/tour Subscribe to Our Newsletter: https://mailchi.mp/jimmydorecomedy/ytlivestreams LIVESTREAM & LIVE SHOW ANNOUNCEMENTS: Email: https://mailchi.mp/jimmydorecomedy/ytlivestreams Twitter: https://twitter.com/jimmy_dore Facebook: https://www.facebook.com/JimmyDoreShow Instagram: https://www.instagram.com/thejimmydoreshow WATCH / LISTEN FREE: Videos: https://www.jimmydore.com Podcasts: https://www.jimmydore.com (Also available on iTunes, Apple Podcasts, Spotify, Google Podcasts, or your favorite podcast player.) ACCESS TO FULL REPLAYABLE LIVESTREAMS: Become a Premium Memb